Pharmacy :: Bayer Outlines New Global R&D Structures
Bayer HealthCare announced today a structural realignment of its global pharmaceutical research and development organization. The company also outlined its future U.S. pharma site plan, and said that New Jersey will be home to its U.S. headquarters for pharmaceuticals. These moves follow Bayer?s acquisition of Schering AG, Germany in June 2006 and are part of the company?s plan to integrate its pharmaceutical operations with those of Schering AG and Berlex Inc. (the U.S. subsidiary of Schering AG).